Neuromodulation for Refractory Epilepsy

Philippe Ryvlin1* and Lara E. Jehi2

1Department of Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland
2Epilepsy Center, Cleveland Clinic, Cleveland, OH, USA
*Correspondence: Philippe Ryvlin, Department of Clinical Neurosciences, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), BH10/137, CHUV, Rue du Bugnon 46, Lausanne 1011, Switzerland. Email: Philippe.Ryvlin@chuv.ch

Abstract
Three neuromodulation therapies, all using implanted device and electrodes, have been approved to treat adults with drug-resistant focal epilepsy, namely, the vagus nerve stimulation in 1995, deep brain stimulation of the anterior nucleus of the thalamus (ANT-DBS) in 2018 (2010 in Europe), and responsive neurostimulation (RNS) in 2014. Indications for VNS have more recently extended to children down to age of 4. Limited or anecdotal data are available in other epilepsy syndromes and refractory/super-refractory status epilepticus. Overall, neuromodulation therapies are palliative, with only a minority of patients achieving long-term seizure freedom, justifying favoring such treatments in patients who are not good candidates for curative epilepsy surgery. About half of patients implanted with VNS, ANT-DBS, and RNS have 50% or greater reduction in seizures, with long-term data suggesting increased efficacy over time. Besides their impact on seizure frequency, neuromodulation therapies are associated with various benefits and drawbacks in comparison to antiseizure drugs. Yet, we lack high-level evidence to best position each neuromodulation therapy in the treatment pathways of persons with difficult-to-treat epilepsy.

Keywords
neuromodulation, vagus nerve stimulation, responsive neurostimulation, deep brain stimulation, drug-resistant epilepsy

Introduction
It has been almost 50 years since the first attempt to control seizures with chronic electrical stimulation of the nervous system.1 Yet, the first appropriately powered and designed randomized controlled trial (RCT) of neuromodulation for epilepsy, targeting the left vagus nerve, was only published in 1995,2 leading to the approval by the U.S. Food and Drug Administration (FDA) of vagus nerve stimulation (VNS) as an adjunctive treatment for drug-resistant focal epilepsy in 1997. Since then, only 2 other neuromodulation therapies benefited from appropriate pivotal RCTs and were subsequently approved by the FDA within the last decade, deep brain stimulation of the anterior nucleus of the thalamus (ANT-DBS) and responsive neurostimulation of the epileptogenic zone(s) (RNS).3,4 In parallel, an upgraded VNS device, offering closed-loop tachycardia-responsive stimulation, has been made available in the last 5 years.5,6 Approved neuromodulation therapies are all indicated in adults with drug-resistant focal epilepsy,7 defined as the failure of adequate trials of 2 tolerated and appropriately chosen and used antiseizure medications (ASMs) to achieve sustained seizure freedom.8 Yet, ANT-DBS requires the failure of 3 ASMs, and VNS benefits from broader indications in children down to age of 4.7 VNS is approved in much of the world; RNS only in the United States; and ANT-DBS in North America, Europe, and a few other countries.7

Vagus Nerve Stimulation
In 2017, the indications of VNS were extended by the FDA to children ≥ 4 years old,9 in agreement with the upgraded recommendations of the American Academy of Neurology (AAN)
which reported a 50% responder rate (50%-RR) of 55% in this age group. Accordingly, a recent systematic review covering more than 100 pediatric VNS studies reported a pooled prevalence estimate for 50%-RR and seizure freedom of 56% and 12%, respectively. Yet, the only double-blind RCT conducted in children aged 3 to 17 years was negative. The AAN guidelines also concluded that VNS shows increasing efficacy over time. A review of the literature and VNS registry data collating 8423 patients reported consistent long-term 50%-RR increasing up to 63%, and seizure freedom rate up to 8%. However, duration of seizure-free periods remains unclear in most reports. Recent controlled and uncontrolled studies have confirmed the positive impact of VNS on quality of life (QoL). An open-label randomized trial showed that VNS therapy with best medical practice (BMP) was associated with a significantly greater improvement of QoL than BMP alone, with a mean gain of 5.5 points at 12 months. A survey from 5000 VNS-treated epilepsy patients also suggested self-reported benefits in alertness, post-ictal state, cognition, and school or professional achievements. In contrast, controlled studies failed to show a significant effect of VNS on comorbid depression in comparison to controls.

The closed-loop VNS (AspireSR), which triggers vagus nerve stimulation upon detection of pre-defined (supposedly ictal) changes in heart rate, has now largely replaced standard VNS. Yet, true ictal tachycardia, defined as > 100 bpm with at least 55% increase or 35 bpm increase from baseline, was only observed in 16%-17% of seizures recorded with this device. When using a more liberal threshold of ≥ 20% increase in heart rate, up to 66% of seizures could be detected but at the cost of 7 false detections per hour. There is no controlled study comparing closed-loop to standard VNS. Yet, several uncontrolled studies reported improved seizure control following replacement of the latter by the former in 31% to 41% of cases. Furthermore, one- to two-thirds of non-responders to standard VNS responded to the AspireSR.

VNS has been used off-label in several epileptic disorders, in particular, generalized epilepsies. The AAN has recommended that VNS may be considered for Lennox-Gastaut syndrome (LGS), where the 50%-RR was estimated at 55%. Comparable benefits were reported in Dravet syndrome, refractory idiopathic/primary generalized epilepsies, and CDKL5 disorder. VNS has also been claimed to effectively control atomic seizures as an alternative to corpus callosotomy. However, a recent meta-analysis of 31 studies involving 533 children showed that callosotomy was more effective than VNS at a cost of greater adverse events, including twice as many reoperations and a 14% rate of symptomatic disconnection syndrome. A recent meta-analysis reported 38 cases with refractory (RSE) or super-refractory (SRSE) status epilepticus, where limited or no alternative treatments was available, who were treated with VNS, including 28 whose status was controlled. However, RSE/SRSE ceased more than 10 days after implantation in half of these patients, calling into question the role of VNS in controlling status.

The cost-effectiveness of VNS has been confirmed in several studies showing decreased hospitalization and emergency visits, status epilepticus, intensive care unit costs, and antiepileptic drugs’ prescription, but increased outpatient resource use. Overall, most studies reported decreased direct healthcare costs following VNS therapy. Yet, cost-savings largely vary between series and countries, with average direct costs of VNS treatment ranging as much as from 75 to 2333 dollars per month.

While no new VNS-related side-effect has been reported, more evidence was collected regarding the significant risk of de novo or aggravating sleep breathing disorders in up to 57% of patients.

Deep Brain Stimulation of the Anterior Nucleus of the Thalamus (ANT-DBS)

Following a positive pivotal RCT performed in 109 adult patients with drug-resistant focal epilepsy (SANTE trial), ANT-DBS was approved in Europe in 2010 and in the USA in 2013. The long-term open-label extension study of the SANTE trial has shown improving efficacy in patients continuing ANT-DBS. At 7 years of follow-up, the median reduction in seizure frequency and the proportion of 50% responders reached ~70% and 74%, respectively. In addition, 16% of patients enjoyed a seizure-free period ≥ 6 months during follow-up, but no long-term seizure freedom was observed. Yet, 34% of patients discontinued ANT-DBS at the longest follow-up, with another 21% considered not evaluable due to missing data. If one considers all discontinuations and lack of evaluable data as treatment failures, the proportion of 50%-RR remains stable over time and is closer to 40% than 74%. Previous treatment with VNS does not seem to influence the chances of responding to ANT-DBS. A few case reports have found ANT-DBS to be effective in controlling RSE and antiGAD-associated TLE.

ANT-DBS is associated with the classic risks of implant site infection and pain, the latter being reported in up to 20% of patients. During RCT, stimulation of ANT was associated with significantly more frequent mood and memory complaints (15% and 13%, respectively) than sham stimulation (1.8%). At 7 years of follow-up, more than 30% of patients reported mood or memory disorders, with 10% expressing suicidality, two-thirds of whom had a past-history of depression prior to ANT-DBS treatment. Yet, objective assessments do not necessarily support patients’ subjective complaints, and some improvement is reported over time or with reduction in stimulation intensity.

Responsive Neurostimulation (RNS)

Following a positive pivotal RCT performed in 191 adult patients with drug-resistant focal epilepsy, RNS was approved by the FDA in 2014. The long-term open-label extension study has reported up to 9 years of follow-up, showing a progressive increase in seizure control over time. In patients continuing RNS, the median reduction in seizure frequency and proportion
of 50%-RR reached −72% and 73%, respectively, while 28% of patients enjoyed seizure-free periods > 6 months.51,52 Yet, 37% of patients discontinued RNS at the longest follow-up, with another 6% considered not evaluable due to missing data. As for ANT-DBS, if one considers all discontinuations and lack of evaluable data as treatment failures, the proportion of 50%-RR remains stable over time and closer to 40% than 73%. Improvement in QoL was also observed with RNS, including on cognitive and seizure worry subscores.4,51

While RNS typically targets cortical epileptogenic zone(s), it was also used successfully in a few patients to stimulate the thalamus, including the centromedian/ventrolateral thalamus bilaterally in a patient with drug-refractory Jeavons syndrome,53 and the right anterior nucleus of the thalamus in an adult with childhood onset genetic generalized epilepsy.54 Positive outcome of RNS was also reported in 4 patients with anti-GAD-associated TLE55 and in 1 patient with SRSE.56

RNS provides unique intracerebral EEG data which can reliably give information on the epileptic activity of the recorded brain regions and offer additional benefits. In particular, RNS might demonstrate that some patients with suspected bitemporal epilepsy primarily suffer from a single or predominant seizure-onset zone, leading to successful unilateral temporal lobe epilepsy surgery.57,58 Another application lies in the possibility to delineate patient’s specific seizure cycles, which could enable clinically relevant seizure forecasting.59-61 RNS-recorded data might also help to predict the long-term response to antiseizure drug shortly after its initiation.61

Infection at the RNS implant site amounts to 4% per surgical procedure and 12% of patients overall after 9 years of follow-up.51 It usually only involves soft tissue, but still requires explantation in half of cases. Intracranial hemorrhage was reported in 3% of patients, with 1% associated with neurologic sequelae. In contrast with ANT-DBS, no cognitive side-effect was reported with RNS. On the contrary, some improvement was observed in neuropsychological performances, in relation to the brain regions stimulated.62 Suicidality was reported in 10% of patients, 86% of which had a past history of mood disorders prior to RNS treatment.51 This is to compare with the prevalence of suicidality reported in epilepsy in general, which often ranges between 20% and 35%.63-65

Areas for Future Research

Despite the wealth of data collected through observational studies or clinical trials, several unanswered questions remain.

Impact on SUDEP Risk

Two underpowered and 1 large-scale VNS studies, providing 6170 and 277,661 patient-years (PYs) of follow-up, respectively, investigated the evolution of the SUDEP rate as a function of the duration of VNS treatment.66-68 Only the large-scale study reported a significant decrease of SUDEP rate over time.68 However, due to the lack of appropriate controls, one cannot assess the proper role of VNS in mediating the reduction in SUDEP incidence. In a nationwide population-based case-control study, VNS treatment was associated with a significantly lower risk of SUDEP as compared to no such treatment with an odds ratio of .41 (95% CI: .17-.98).69 As for other forms of neurostimulation therapy, the rate of probable or definite SUDEP in patients undergoing ANT-DBS and RNS was calculated at 2.9/1000 PYs (95% CI: .3-10.4) and 2.8/1000 PYs (95% CI: 1.2-6.7),51 respectively, corresponding to the lower margin of the SUDEP figures reported in drug-resistant epilepsy.

Biomarkers Predicting Response to Therapy

Reliable predictors of therapeutic response are lacking across neuromodulation options. Non-lesional epilepsy and generalized seizure type were found associated with greater VNS efficacy but with a very modest odds ratio,13 while the role of age remains debated.12,70-72 Several neurophysiological and neuroimaging predictors are being investigated but are not yet validated in clinical practice.73-76 Similarly, we lack biomarkers to predict response to ANT-DBS, with some reports suggesting the potential value of temporal theta-band desynchronization,77 hippocampal-evoked potentials,78 and increased functional connectivity between ANT and the default mode network.79 The exact position of ANT-DBS electrodes might also prove important, with some data suggesting better seizure control when stimulating the anterior half of ANT80,81 or its junction with the mammillothalamic tract.52,83 The transventricular lead trajectory appears more effective than the extraventricular one to reach the appropriate target, without difference in safety between the 2 methods.84,85 No biomarker exists either to predict the clinical response to RNS.

Comparative Effectiveness

No robust observational data or RCT data exist to meaningfully compare effectiveness across neuromodulation therapies. Two uncontrolled retrospective studies compared the effectiveness of RNS and VNS in a total of 53 patients, showing no significant difference in patients’ profiles, median reduction in seizure frequency, and seizure-free rates.86,87 Also, of interest is the proportion of patients who responded to ANT-DBS or RNS after having failed VNS. In the SANTE trial, 45% of patients had been previously treated with VNS, and these were found to equally benefit from ANT-DBS than the other patients.3 Another series of 7 patients who failed VNS and were subsequently treated with ANT-DBS reported a 71% RR.45 Similarly, patients who failed VNS demonstrated a similar response to RNS as those not previously treated with VNS.4,51

Seizure freedom Versus Remission

Reported rates of seizure freedom in neuromodulation studies actually refer to periods of seizure-remission of varying duration, typically between 6 and 12 months, observed by the date of last follow-up during open-label extension phases of
clinical study. Considering that the estimated cumulative probability of 12-month seizure-remission is 33.4% at 7 years in patients with drug-resistant epilepsy using medical therapy alone and that surgical series typically report complete seizure freedom since surgery (for example, an Engel score of 1 is equivalent to sustained seizure freedom since surgery and not terminal remission), ascertaining the true contribution of neuromodulation to observed remission 7 or 9 years after device implantation is difficult and will require further evaluation.

Conclusion

Many neuromodulation therapies and brain targets have been proposed for epilepsy, but only 4 appropriately designed RCTs have been performed in the field. Furthermore, these RCTs concentrated on demonstrating the antiseizure efficacy of active vs sham stimulation, with no evidence gathered to delineate the optimal timing for offering such therapies during the course of drug-resistant epilepsy or guide the choice or order of the different neuromodulation methods. Accordingly, neuromodulation should be currently primarily offered to patients with refractory epilepsy who are not, or who are poor candidates for curative epilepsy surgery. Decision regarding the type of neuromodulation should be discussed with patients and caregivers based on a fair presentation of the expected risks and benefits associated with each type of therapy.

Acknowledgments

We wish to thank Lawrence Hirsch, Sylvain Rheims, and Arseny Sokolov for providing suggestions for this review.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by EU’s Horizon 2020 Research and Innovation Programme; 785907 (HBP SGA2); 945539 (HBP SGA3).

ORCID iD

Philippe Ryvlin https://orcid.org/0000-0001-7775-6576

References

1. Cooper IS, Amin I, Gilman S. The effect of chronic cerebellar stimulation upon epilepsy in man. Trans Am Neurol Assoc. 1973; 98:192-196.
2. A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. the vagus nerve stimulation study group. Neurology 1995; 45(2): 224-230.
3. Fisher R, Salanova V, Witt T, et al. Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy. Epilepsia. 2010;51(5):899-908.
4. Morrell MJ, Group RNSSiES. responsive cortical stimulation for the treatment of medically intractable partial epilepsy. Neurology. 2011;77(13):1295-1304.
5. Fisher RS, Afra P, Macken M, et al. Automatic vagus nerve stimulation triggered by ictal tachycardia: clinical outcomes and device performance-the U.S. E-37 trial. Neuromodulation: Technology at the Neural Interface. 2016;19(2):188-195.
6. Boon P, Vonck K, van Rijckevoorsel K, et al. A prospective, multicenter study of cardiac-based seizure detection to activate vagus nerve stimulation. Seizure. 2015;32:52-61.
7. Ryvlin P, Rheims S, Hirsch LJ, Sokolov A, Jehl N. Neuromodulation in epilepsy: state-of-the-art approved therapies. Lancet Neurol. 2021.
8. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia. 2010; 51(6):1069-1077.
9. Fan JJ, Shan W, Wu JP, Wang Q. Research progress of vagus nerve stimulation in the treatment of epilepsy. CNS Neurosci Ther. 2019; 25(11):1222-1228.
10. Morris GL, 3rd, Gloss D, Buchhalter J, Mack KJ, Nickels K, Harden C. Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: report of the guideline development subcommittee of the american academy of neurology. Neurology. 2013;81(16):1453-1459.
11. Jain P, Arya R. Vagus nerve stimulation and seizure outcomes in pediatric refractory epilepsy: systematic review and meta-analysis. Neurology 2021;Epub ahead of print:PMID: 33849993. https://doi.org/10.1212/WNL.0000000000012030.
12. Klinkenberg S, Aalbers MW, Vles JSH, et al. Vagus nerve stimulation in children with intractable epilepsy: a randomized controlled trial. Dev Med Child Neurol. 2012;54(9):855-861.
13. Englot DJ, Rolston JD, Wright CW, Hassnain KH, Chang EF. Rates and predictors of seizure freedom with vagus nerve stimulation for intractable epilepsy. Neurosurgery. 2016;79(3): 345-353.
14. Ryvlin P, Gilliam FG, Nguyen DK, et al. The long-term effect of vagus nerve stimulation on quality of life in patients with pharmaco-resistant focal epilepsy: The pulse (open prospective randomized long-term effectiveness) trial. Epilepsia. 2014;55(6): 893-900.
15. Englot DJ, Hassnain KH, Rolston JD, Harward SC, Sinha SR, Haglund MM. Quality-of-life metrics with vagus nerve stimulation for epilepsy from provider survey data. Epilepsy Behav. 2017;66: 4-9.
16. Harden CL, Pulver MC, Radvin LD, Nikolov B, Halper JP, Labar DR. A pilot study of mood in epilepsy patients treated with vagus nerve stimulation. Epilepsy Behav. 2000;1(2):93-99.
17. Elger G, Hoppe C, Falkai P, Rush AJ, Elger CE. Vagus nerve stimulation is associated with mood improvements in epilepsy patients. Epilepsy Research. 2000;42(2-3):203-210.
18. Klinkenberg S, van den Bosch CNCJ, Majoie HJM, et al. Behavioural and cognitive effects during vagus nerve stimulation in...
children with intractable epilepsy - a randomized controlled trial. *Eur J Paediatr Neurol*. 2013;17(1):82-90.

19. Hamilton P, Soryal I, Dhahri P, et al. Clinical outcomes of VNS therapy with AspireSR (including cardiac-based seizure detection) at a large complex epilepsy and surgery centre. *Seizure*. 2018;58:120-126.

20. Kawaji H, Yamamoto T, Fujimoto A, et al. Additional seizure reduction by replacement with vagus nerve stimulation model 106 (AspireSR). *Neurosci Lett*. 2020;716:134636.

21. Lo WB, Chevill B, Philip S, Agrawal S, Walsh AR. Seizure improvement following vagus nerve stimulator (VNS) battery change with cardiac-based seizure detection automatic stimulation (AutoStim): early experience in a regional paediatric unit. *Child's Nerv Syst*. 2021;37(4):1237-1241.

22. Dibué M, Greco T, Spoore JKH, et al. Vagus nerve stimulation in patients with lennox-gastaut syndrome: a meta-analysis. *Acta Neurol Scand*. 2021;143(5):497-508.

23. Dibué-Adjei M, Fischer I, Steiger H-J, Kamp MA. Effect of adjunctive vagus nerve stimulation in patients with dravet syndrome: a meta-analysis of 68 patients. *Seizure*. 2017;50:147-152.

24. Ng M, Devinsky O. Vagus nerve stimulation for refractory idiopathic generalised epilepsy. *Seizure*. 2004;13(3):176-178.

25. Holmes MD, Silbergeld DL, Drouhard D, Wilensky AJ, Ojemann LM. Effect of vagus nerve stimulation on adults with pharmaco-resistant generalized epilepsy syndromes. *Seizure*. 2004;13(5):340-345.

26. Kostov H, Larsson PG, Røste GK. Is vagus nerve stimulation a treatment option for patients with drug-resistant idiopathic generalised epilepsy? *Acta Neurol Scand*. 2007;115:55-58.

27. Elliott RE, Rodgers SD, Bassani L, et al. Vagus nerve stimulation for children with treatment-resistant epilepsy: a consecutive series of 141 cases. *J Neurosurg Pediatr*. 2011;7(5):491-500.

28. Arya R, Greiner HM, Lewis A, et al. Vagus nerve stimulation for medically refractory absence epilepsy. *Seizure*. 2013;22(4):267-270.

29. Welch WP, Sitwat B, Sagowa Y. Use of vagus nerve stimulator on children with primary generalized epilepsy. *J Child Neurol*. 2018;33(7):449-452.

30. Lim Z, Wong K, Downs J, Bebbington K, Demarest S, Leonard H. Vagus nerve stimulation for the treatment of refractory epilepsy in the CDKL5 deficiency disorder. *Epilepsy Res*. 2018;146:36-40.

31. Ye VC, Mansouri A, Warsi NM, Ibrahim GM. Atonic seizures in children: a meta-analysis comparing corpus callosotomy to vagus nerve stimulation. *Child's Nerv Syst*. 2021;37(1):259-267.

32. Dibué-Adjei M, Brigo F, Yamamoto T, Vonck K, Trinka E. Vagus nerve stimulation in refractory and super-refractory status epilepticus - a systematic review. *Brain Stimulati*. 2019;12(5):1101-1110.

33. Ben-Menachem E, Hellström K, Verstappen D. Analysis of direct hospital costs before and 18 months after treatment with vagus nerve stimulation therapy in 43 patients. *Neurology*. 2002;59(6 suppl 4):S44-S47.

34. Helmers SL, Duh MS, Guérin A, et al. Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy. *Epilepsy Behav*. 2011;22(2):370-375.

35. Helmers SL, Duh MS, Guérin A, et al. Clinical outcomes, quality of life, and costs associated with implantation of vagus nerve stimulation therapy in pediatric patients with drug-resistant epilepsy. *Eur J Paediatr Neurol*. 2012;16(5):449-458.

36. Campbell C, Smithson WH, Bunker M, Burke T, Hughes D. Impact of vagus nerve stimulation on secondary care burden in children and adults with epilepsy: review of routinely collected hospital data in England. *Epilepsy Behav*. 2015;52(Pt A):68-73.

37. Jemmum P, Sabers A, Christensen J, Ibsen R, Kjellberg J. Socio-economic evaluation of vagus stimulation: a controlled national study. *Seizure*. 2016;42:15-19.

38. Kopciuch D, Barciszewska AM, Flicinski J, et al. Economic and clinical evaluation of vagus nerve stimulation therapy. *Acta Neurol Scand*. 2019;140(4):244-251.

39. de Kinderen RJ, Postulart D, Aldenkamp AP, et al. Cost-effectiveness of the ketogenic diet and vagus nerve stimulation for the treatment of children with intractable epilepsy. *Epilepsy Res*. 2015;110:119-131.

40. Marzec M, Edwards J, Sagerh O, Fromes G, Malow BA. Effects of vagus nerve stimulation on sleep-related breathing in epilepsy patients. *Epilepsia*. 2003;44(7):930-935.

41. Zambrilli E, Sai bene AM, Furia F, et al. Laryngeal motility alteration: a missing link between sleep apnea and vagus nerve stimulation for epilepsy. *Epilepsia*. 2016;57(1):e24-e27.

42. Salvadé A, Ryvlin P, Rossetti AO. Impact of vagus nerve stimulation on sleep-related breathing disorders in adults with epilepsy. *Epilepsy Behav*. 2018;79:126-129.

43. Salanova V, Sperling MR, Gross RE, et al. The SANTÉ study at 10 years of follow-up: effectiveness, safety, and sudden unexpected death in epilepsy. *Epilepsia*. 2021;62(6):1306-1317.

44. Salanova V, Witt T, Worth R, et al. Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy. *Neurology*. 2015;84(10):1017-1025.

45. Park HR, Choi SJ, Joo EY, et al. The role of anterior thalamic deep brain stimulation of the anterior nucleus of the thalamus disrupts sleep in epilepsy patients. *Eur J Paediatr Neurol*. 2012;16(5):449-458.

46. Salanova V, Sperling MR, Gross RE, et al. The SANTÉ study at 10 years of follow-up: effectiveness, safety, and sudden unexpected death in epilepsy. *Epilepsia*. 2021;62(6):1306-1317.

47. Salanova V, Witt T, Worth R, et al. Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy. *Neurology*. 2015;84(10):1017-1025.

48. Park HR, Choi SJ, Joo EY, et al. The role of anterior thalamic deep brain stimulation as an alternative therapy in patients with previously failed vagus nerve stimulation for refractory epilepsy. *Epilepsia*. 2019;97(3):176-182.

49. Lee C-Y, Lim S-N, Wu T, Lee S-T. Successful treatment of refractory status epilepticus using anterior thalamic nuclei deep brain stimulation. *World Neurosurgery*. 2017;99:14-18.

50. Yuan L, Zhang S, Liang S, Liu N, Yu X, Liang S. Deep brain stimulation of the anterior nucleus of the thalamus in a patient with super-refractory convulsive status epilepticus. *Epileptic Disorders: International Epilepsy Journal with Videotape*. 2019;21(4):379-384.

51. Gillinder L, Lehn A, Papacostas J, Olson S, Blum S, Dionisio S. Refractory epilepsy secondary to anti-GAD encephalitis treated with DBS post SEEG evaluation: a novel case report based on stimulation findings. *Epileptic Disorder*. 2018;20(5):451-456.

52. Tröster AI, Meador KJ, Irwin CP, Fisher RS, Group SS. Memory and mood outcomes after anterior thalamic stimulation for refractory partial epilepsy. *Seizure*. 2017;45:133-141.

53. Voges BR, Schmitt FC, Hamel W, et al. Deep brain stimulation of anterior nucleus thalami disrupts sleep in epilepsy patients. *Epilepsia*. 2015;56(8):e99-e103.
51. Nair DR, Laxer KD, Weber PB, et al. Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy. Neurology. 2020;95(9):e1244-e1256.

52. Bergey GK, Morrell MJ, Mizrahi EM, et al. Long-term treatment with responsive brain stimulation in adults with refractory partial seizures. Neurology. 2015;84(8):810-817.

53. Kokkinos V, Urban A, Siesterson ND, Li N, Corson D, Richardson RM. Responsive neurostimulation of the thalamus improves seizure control in idiopathic generalized epilepsy: a case report. Neurosurgery. 2020;87(5):E578-E583.

54. Herlopian A, Cash SS, Eskandar EM, Jennings T, Cole AJ. Responsive neurostimulation targeting anterior thalamic nucleus in generalized epilepsy. Annals of Clinical and Translational Neurology. 2019;6(10):2104-2109.

55. Feyissa AM, Mirro EA, Wabulya A, Tatum WO, Wilmer-Fierro KE, Won Shin H. Brain-responsive neurostimulation treatment in patients with GAD65 antibody-associated autoimmune mesial temporal lobe epilepsy. Epilepsia Open. 2020;5(2):307-313.

56. Ernst LD, Krause KL, Kellogg MA, Raslan AM, Spencer DC. Novel use of responsive neurostimulation (rns system) in the treatment of super refractory status epilepticus. J Clin Neuropysiol. 2019;36(3):242-245.

57. King-Stephens D, Mirro E, Weber PB, et al. Lateralization of mesial temporal lobe epilepsy with chronic ambulatory electrocorticography. Epilepsia. 2015;56(6):959-967.

58. Hirsch LJ, Mirro EA, Salanova V, et al. Mesial temporal resection following long-term ambulatory intracranial EEG monitoring with a direct brain-responsive neurostimulation system. Epilepsia. 2020;61(3):408-420.

59. Proix T, Truccolo W, Leguia MG, et al. Forecasting seizure risk in adults with focal epilepsy: a development and validation study. Lancet Neurol. 2021;20(2):127-135.

60. Baud MO, Rao VR. Gauging seizure risk. Neurology. 2018;91(21):967-973.

61. Quraishi IH, Mercier MR, Skarpaas TL, Hirsch LJ. Early detection rate changes from a brain-responsive neurostimulation system predict efficacy of newly added antiseizure drugs. Epilepsia. 2020;61(1):138-148.

62. Loring DW, Kapur R, Meador KJ, Morrell MJ. Differential neuropsychological outcomes following targeted responsive neurostimulation for partial-onset epilepsy. Epilepsia. 2015;56(11):1836-1844.

63. Friedman D, Spruill TM, Liu H, et al. Depressive symptoms and suicidality among individuals with epilepsy enrolled in self-management studies: results from the US centers for disease control and prevention managing epilepsy well (MEW) network. Epilepsy Behav. 2018;87:235-240.

64. Hamed SA, Elserogy YB, Abdou MA, Abdellah MM. Risks of suicidality in adult patients with epilepsy. World J Psychiatry. 2012;2(2):33-42.

65. Mula M, Bell GS, Sander JW. Suicidality in epilepsy and possible effects of antiepileptic drugs. Curr Neurol Neurosci Rep. 2010;10(4):327-332.

66. Annegers JF, Coan SP, Hauser WA, Leestma J. Epilepsy, vagal nerve stimulation by the NCP system, all-cause mortality, and sudden, unexpected, unexplained death. Epilepsia. 2000;41(5):549-555.

67. Granbichler CA, Nashef L, Selway R, Polkey CE. Mortality and SUDEP in epilepsy patients treated with vagus nerve stimulation. Epilepsia. 2015;56(2):291-296.

68. Ryvlin P, So EL, Gordon CM, et al. Long-term surveillance of SUDEP in drug-resistant epilepsy patients treated with VNS therapy. Epilepsia. 2018;59(3):562-572.

69. Sveinsson O, Andersson T, Mattsson S, Carlsson S, Tomson T. Clinical risk factors in SUDEP. Neurology. 2020;94(4):e419-e429.

70. Englot DJ, Chang EF, Auguste KI. Efficacy of vagus nerve stimulation for epilepsy by patient age, epilepsy duration, and seizure type. Neurosurg Clin. 2011;22:443-448.

71. Zhu J, Xu C, Zhang X, et al. Epilepsy duration as an independent predictor of response to vagus nerve stimulation. Epilepsia Res. 2020;167:106432.

72. Russo A, Hyslop A, Gentile V, et al. Early implantation as a main predictor of response to vagus nerve stimulation in childhood-onset refractory epilepsy. J Child Neurol. 2021;36(5):365-370.

73. Hödl S, Carrette S, Meurs A, et al. Neurophysiological investigations of drug resistant epilepsy patients treated with vagus nerve stimulation to differentiate responders from non-responders. Eur J Neurol. 2020;27(7):1178-1189.

74. Mithani K, Mikhail M, Morgan BR, et al. Connectomic profiling identifies responders to vagus nerve stimulation. Ann Neurol. 2019;86(5):743-753.

75. Mithani K, Wong SM, Mikhail M, et al. Somatosensory evoked fields predict response to vagus nerve preoperative. Neuroimage: Clinic. 2020;26:102025.

76. Liu H-Y, Yang Z, Meng F-G, et al. Preoperative heart rate variability as predictors of vagus nerve stimulation outcome in patients with drug-resistant epilepsy. Sci Rep. 2018;8(1):3856.

77. Scherer M, Milosevic L, Guggenberger R, et al. Desynchronization of temporal lobe theta-band activity during effective anterior thalamus deep brain stimulation in epilepsy. Neuroimage. 2020;218:116967.

78. Wang Y-C, Kremen V, Brinkmann BH, et al. Probing circuit of papez with stimulation of anterior nucleus of the thalamus and hippocampal evoked potentials. Epilepsia Res. 2020;159:106248.

79. Middlebrooks EH, Grewal SS, Stead M, Lundstrom BN, Worrell GA, Van Gompel JJ. Differences in functional connectivity profiles as a predictor of response to anterior thalamic nucleus deep brain stimulation for epilepsy: a hypothesis for the mechanism of action and a potential biomarker for outcomes. Neurosurg Focus. 2018;45(2):E7.

80. Lehtimäki K, Möttönen T, Järventaus K, et al. Outcome based definition of the anterior thalamic nucleus deep brain stimulation target in refractory epilepsy. Brain Stimulation. 2016;9(2):268-275.

81. Guo Z, Feng Z, Wang Y, Wei X. Simulation study of intermittent axonal block and desynchronization effect induced by high-frequency stimulation of electrical pulses. Front Neurosci. 2018;12:858.

82. Krishna V, King NKK, Sammartino F, et al. Anterior nucleus deep brain stimulation for refractory epilepsy. Neurosurgery. 2016;78(6):802-811.

83. Schaper FLWJ, Plantinga BR, Colon AJ, et al. Deep brain stimulation in epilepsy: a role for modulation of the mammillothalamic tract in seizure control? Neurosurgery. 2020;87(3):602-610.
84. Lehtimäki K, Coenen VA, Gonçalves Ferreira A, et al. The surgical approach to the anterior nucleus of thalamus in patients with refractory epilepsy: experience from the international multicenter registry (MORE). *Neurosurgery*. 2019;84(1):141-150.

85. Jehi L, Morita-Sherman M, Love TE, et al. Comparative effectiveness of stereo-eeg versus subdural grids in epilepsy surgery. *Ann Neurol*. 2021.

86. Wang AJ, Bick SK, Williams ZM. Vagus nerve stimulation versus responsive neurostimulator system in patients with temporal lobe epilepsy. *Stereotact Funct Neurosurg*. 2020;98(1):21-29.

87. Ellens NR, Elisevich K, Burdette DE, Patra SE. A comparison of vagal nerve stimulation and responsive neurostimulation for the treatment of medically refractory complex partial epilepsy. *Stereotact Funct Neurosurg*. 2018;96(4):259-263.

88. Callaghan B, Schlesinger M, Rodemer W, et al. Remission and relapse in a drug-resistant epilepsy population followed prospectively. *Epilepsia*. 2011;52(3):619-626.

89. Handforth A, DeGiorgio CM, Schachter SC, et al. Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. *Neurology*. 1998;51(1):48-55.